Amanda L. Sharpe, Ph.D.
The Sharpe lab is interested in understanding the contribution of neuropeptides such as proopiomelanocortin, neurotensin, and corticotropin releasing factor to addiction, obesity, and age-related cognitive impairment, and in the development of therapeutics to treat these conditions. We use behavioral (operant conditioning), anatomical, pharmacological, and molecular approaches to address our research questions, often in combination with genetic mouse models. We are interested in the normal physiological role for these neuropeptides, as well as the adaptations that occur in this neurocircuitry under the conditions of obesity, food restriction, and chronic drug use. The long-term goals of our lab are to 1) elucidate the pharmacology and neurocircuitry involved in the regulation of appetite for and consumption of rewards (both food and drug), and 2) to determine the contribution of hypothalamic neuropeptides to age-related conditions such as obesity and cognitive decline.
Education & Experience
B.S. in Pharmacy
Ohio Northern University, Ada, OH1997
Ph.D. in Pharmacology
Wake Forest University, Winston-Salem, NC2002
Postdoc in Behavioral Neuroscience
Oregon Health & Science University, Portland, OR2007
Effect of obesity on proopiomelanocortin regulation of reward and feeding
Presbyterian Health Foundation07/01/2018 - 06/30/2019
Effects of dietary restriction on age-related neurophysiological adaptations: From behavior to single dopaminergic neurons
Oklahoma Medical Research Foundation05/01/2018 - 04/30/2021
Publications & Presentations
- 16. Pastor R, Reed C, Burkhart-Kasch S, Li N, Sharpe A, Coste S C, Stenzel-Poore M P, Phillips T J. Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout mice. Psychopharmacology. 2011; 218 : 169-77
17. Sharpe A, Phillips T J. Central urocortin 3 administration decreases limited-access ethanol intake in nondependent mice. Behavioural pharmacology. 2009; 20 : 346-51
18. Sharpe A, Low M J. Proopiomelanocortin peptides are not essential for development of ethanol-induced behavioral sensitization. Alcoholism, clinical and experimental research. 2009; 33 : 1202-7
19. Sharpe A, Coste S C, Burkhart-Kasch S, Li N, Stenzel-Poore M P, Phillips T J. Mice deficient in corticotropin-releasing factor receptor type 2 exhibit normal ethanol-associated behaviors. Alcoholism, clinical and experimental research. 2005; 29 : 1601-9
20. Sharpe A, Tsivkovskaia N O, Ryabinin A E. Ataxia and c-Fos expression in mice drinking ethanol in a limited access session. Alcoholism, clinical and experimental research. 2005; 29 : 1419-26
- 1. Plasticity of GABA input to VTA dopamine neurons in opioid use disorders. Misc Federal. Start Date: 2021. End Date: 2025.
2. The role of proopiomelanocortin neurons in age-related cognitive decline. NIH. Start Date: 2019. End Date: 2022.
3. Effects of dietary restriction on age-related neurophysiological adaptations: from behavior to single dopaminergic neurons. NIH. Start Date: 2016. End Date: 2021.
4. Effects of obesity on proopiomelanocortin regulation of reward and feeding. Non-federal. Start Date: 2018. End Date: 2019.
Awards and Honors
- 1. . Harold Hamm Diabetes Center Travel Award. Date: 2019.
- 1. Degree: Post-doctoral fellowship. Oregon Health Sciences University. Date: 2008.
2. Degree: Ph D. Wake Forest University. Date: 2002.
3. Degree: B. Pharm. Ohio Northern University. Date: 1997.